Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043671 | 0.76 | MEN1 (0.42) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL6043665 | 0.76 | MEN1 (0.42) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL8580077 | 0.76 | L3MBTL1 (0.59) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL30763935 | 0.76 | MEN1 (0.44) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL9673263 | 0.75 | MEN1 (0.53) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL3168977 | 0.72 | MEN1 (0.46) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL11024894 | 0.71 | MEN1 (0.54) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL6000386 | 0.70 | MEN1 (0.48) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL6708639 | 0.70 | MEN1 (0.46) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL23219868 | 0.69 | L3MBTL1 (0.57) | L3MBTL1MEN1KMT2AKDM4CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| EP-2086964-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | Astra Zeneca AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| EP-1891058-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GCK, GCKR, GK | L3MBTL1 4347/4885MEN1 3245/4885KMT2A 2218/4885 |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | HK1, GCKR, GCK | L3MBTL1 4574/4885MEN1 1265/4885KMT2A 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.